Antipsychotics

A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.

Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.

In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.

Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.

People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.

A review of the scientific literature related to the withdrawal of antipsychotics: animal studies, withdrawal symptoms, tapering success rates, and consumer accounts of discontinuation.

This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.

Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.

In JAMA psychiatry, researchers outline new theories connecting antipsychotic use in people with schizophrenia and increased dementia risk.

People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.

Study finds that 74% of patients with a psychotic disorder off antipsychotics at end of 10 years are in remission.

The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.

Study finds that reduced cortical thickness and brain surface area associated with 'schizophrenia' may result from antipsychotic drug use.

Common second-generation antipsychotic medications are causing symptoms of obsessive-compulsive disorder to emerge in many people who previously only had schizophrenia symptoms, according to a...

The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.

With increasing evidence that psychiatric drugs do more harm than good over the long term, the field of psychiatry often seems focused on sifting through the mounds of research data it has collected, eager to at last sit up and cry, here’s a shiny speck of gold! Our drugs do work! One recently published study on withdrawal of antipsychotics tells of long-term benefits. A second tells of long-term harm. Which one is convincing?

A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.

The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.

A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.

Finnish reseachers report in Schizophrenia Research that antipsychotic use is associated with cognitive and memory impairments. The University of Oulu team studied forty people...

An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.

A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.